nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Contents
|
|
|
2017 |
31 |
4 |
p. v-vii |
artikel |
2 |
Contributors
|
|
|
2017 |
31 |
4 |
p. iii-iv |
artikel |
3 |
Copyright
|
|
|
2017 |
31 |
4 |
p. ii |
artikel |
4 |
Forthcoming Issues
|
|
|
2017 |
31 |
4 |
p. viii |
artikel |
5 |
Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms
|
Ozkaya, Neval |
|
2017 |
31 |
4 |
p. 705-719 |
artikel |
6 |
Kinase Inhibitor Screening in Myeloid Malignancies
|
Tyner, Jeffrey W. |
|
2017 |
31 |
4 |
p. 693-704 |
artikel |
7 |
Kinase Inhibitors in the Treatment of Myeloid Malignancies
|
Mullally, Ann |
|
2017 |
31 |
4 |
p. ix-x |
artikel |
8 |
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and theĀ Development of Next Generation ABL Kinase Inhibitors
|
Patel, Ami B. |
|
2017 |
31 |
4 |
p. 589-612 |
artikel |
9 |
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
|
Ghiaur, Gabriel |
|
2017 |
31 |
4 |
p. 681-692 |
artikel |
10 |
Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms
|
Meyer, Sara C. |
|
2017 |
31 |
4 |
p. 627-642 |
artikel |
11 |
Targeting Aberrant Signaling in Myeloid Malignancies
|
Sellar, Rob |
|
2017 |
31 |
4 |
p. 565-576 |
artikel |
12 |
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms
|
Hobbs, Gabriela S. |
|
2017 |
31 |
4 |
p. 613-626 |
artikel |
13 |
The Development of FLT3 Inhibitors in Acute Myeloid Leukemia
|
Garcia, Jacqueline S. |
|
2017 |
31 |
4 |
p. 663-680 |
artikel |
14 |
The Treatment of Myeloid Malignancies with Kinase Inhibitors
|
Mullally, Ann |
|
2017 |
31 |
4 |
p. i |
artikel |
15 |
Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis
|
Gotlib, Jason |
|
2017 |
31 |
4 |
p. 643-661 |
artikel |
16 |
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia
|
Radich, Jerald P. |
|
2017 |
31 |
4 |
p. 577-587 |
artikel |